Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2013

01-08-2013 | Gastrointestinal Oncology

Intraperitoneal Cytokine Level in Patients with Peritoneal Surface Malignancies. A Study of the RENAPE (French Network for Rare Peritoneal Malignancies)

Authors: Virginie Vlaeminck-Guillem, MD, PhD, Jacques Bienvenu, MD, PhD, Sylvie Isaac, MD, Blandine Grangier, AD, François Golfier, MD, PhD, Guillaume Passot, MD, Naoual Bakrin, MD, Claire Rodriguez-Lafrasse, MD, PhD, François-Noël Gilly, MD, PhD, Olivier Glehen, MD, PhD

Published in: Annals of Surgical Oncology | Issue 8/2013

Login to get access

Abstract

Background

Prognosis of peritoneal surface malignancies is influenced by the adequacy of surgical and chemotherapeutic treatment and by tumor spread at the time of diagnosis. By promoting morphological changes in the mesothelium, inflammatory cytokines reflect tumor biology and could be evaluated as biomarkers. Our objective was to evaluate intraperitoneal levels of IL-6, IL-8, IL-10, TNF-alpha, and sICAM in patients with pseudomyxoma peritonei and peritoneal mesothelioma.

Methods

Serum and peritoneal fluid samples were prospectively collected in patients managed for peritoneal surface malignancies including pseudomyxoma peritonei (PMP), mesotheliomas, and other rare primitive peritoneal cancers (cancer group) and patients who underwent intraperitoneal laparoscopic surgical procedures for benign diseases (noncancer group). Samples were analyzed for IL-6, IL-8, IL-10, TNF-alpha, and sICAM concentrations. Correlations were assessed with tumor spread related clinical scores.

Results

In both patient groups, intraperitoneal cytokine levels were higher than serum levels. Cancer patients had significantly higher intraperitoneal cytokine levels than noncancer patients. Peritoneal levels tended to increase in cancer patients with free tumor cells in peritoneal fluid. They were significantly higher in patients with tumor implants ≥2 cm and/or patients with peritoneal carcinomatosis index (PCI) >19. Furthermore, patients with malignant pseudomyxoma peritonei (grades II and III) had higher levels than patients with nonmalignant disease (grade I).

Conclusions

Assessment of intraperitoneal IL-6, IL-8, IL-10, TNF-alpha, and sICAM levels can be performed in patients with peritoneal surface malignancies. They can be considered as both diagnostic and prognostic biomarkers that could be used as useful adjuncts for therapeutic decision making.
Appendix
Available only for authorised users
Literature
1.
Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol. 2007;95:93–6.PubMedCrossRef
2.
Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241:300–8.PubMedCrossRef
3.
Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5:219–28.PubMedCrossRef
4.
Sugarbaker PH. Evolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives? Am J Surg. 2011;201:157–9.PubMedCrossRef
5.
Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116:5608–18.PubMedCrossRef
6.
Portilla AG, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg. 1999;23:23–9.PubMedCrossRef
7.
Gilly FN, Carry PY, Sayag AC, Brachet A, Panteix G, Salle B, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology. 1994;41:124–9.PubMed
8.
Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12:649–71.PubMedCrossRef
9.
Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei.” Am J Surg Pathol. 1995;19:1390–408.PubMedCrossRef
10.
Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, et al. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14:2300–8.PubMedCrossRef
11.
Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, et al. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14:500–8.PubMedCrossRef
12.
Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2009;249:243–9.PubMedCrossRef
13.
Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15:526–34.PubMedCrossRef
14.
Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229–37.PubMedCrossRef
15.
Mohamed F, Gething S, Haiba M, Brun EA, Sugarbaker PH. Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process. J Surg Oncol. 2004;86:10–5.PubMedCrossRef
16.
Mochizuki Y, Nakanishi H, Kodera Y, Ito S, Yamamura Y, Kato T, et al. TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clin Exp Metastasis. 2004;21:39–47.PubMedCrossRef
17.
Yonemura Y, Endou Y, Nojima N, Kawamura T, Fujita H, Kaji M, et al. A possible role of cytokines in the formation of peritoneal dissemination. Int J Oncol. 1997;11: 349–58.PubMed
18.
Ziprin P, Ridgway PF, Pfistermuller KL, Peck DH, Darzi AW. ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha: a potential mechanism by which surgical trauma increases peritoneal metastases. Cell Commun Adhes. 2003;10:141–54.PubMed
19.
Sugimoto K, Fujii S, Sago H, Yoshida K, Takemasa T, Yamashita K. Role of marginal stress fibers formed in the rat vascular endothelial cells. Tissue Cell. 1993;25:825–31.PubMedCrossRef
20.
Kimura A, Koga S, Kudoh H, Iitsuka Y. Peritoneal mesothelial cell injury factors in rat cancerous ascites. Cancer Res. 1985;45:4330–3.PubMed
21.
Jacquet P, Sugarbaker P. Influence of wound healing on gastrointestinal cancer recurrence. Wounds. 1995;7:40–7.
22.
Jacquet P, Sugarbaker P: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker P, ed., Peritoneal Carcinomatosis: Principles of Management. Boston, MA: Kluwer Academic Publishers, 1996:359–74.CrossRef
23.
Cheong YC, Shelton JB, Laird SM, Richmond M, Kudesia G, Li TC, et al. IL-1, IL-6 and TNF-alpha concentrations in the peritoneal fluid of women with pelvic adhesions. Hum Reprod. 2002;17:69–75.PubMedCrossRef
24.
Skrzypczak J, Szczepanska M, Puk E, Kamieniczna M, Kurpisz M. Peritoneal fluid cytokines and sICAM-1 in minimal endometriosis: search for discriminating factors between infertility and/or endometriosis. Eur J Obstet Gynecol Reprod Biol. 2005;122:95–103.PubMedCrossRef
25.
Calhaz-Jorge C, Costa AP, Santos MC, Palma-Carlos ML. Soluble intercellular adhesion molecule 1 in the peritoneal fluid of patients with endometriosis correlates with the extension of peritoneal implants. Eur J Obstet Gynecol Reprod Biol. 2003;106:170–4.PubMedCrossRef
26.
Melis M, Pace E, Siena L, et al. Biologically active intercellular adhesion molecule-1 is shed as dimers by a regulated mechanism in the inflamed pleural space. Am J Respir Crit Care Med. 2003;167:1131–8.PubMedCrossRef
27.
Mutti L, Piacenza A, Valenti V, Castagneto B, Betta PG. Expression of intercellular adhesion molecule-1 (ICAM-1) by reactive mesothelial cells in pleural effusions. Pathologica. 1993;85:725–8.PubMed
28.
Nasreen N, Mohammed KA, Hardwick J, Van Horn RD, Sanders KL, Doerschuk CM, et al. Polar production of interleukin-8 by mesothelial cells promotes the transmesothelial migration of neutrophils: role of intercellular adhesion molecule-1. J Infect Dis. 2001;183:1638–45.PubMedCrossRef
29.
Yu G, Tang B, Yu PW, Peng ZH, Qian F, Sun G. Systemic and peritoneal inflammatory response after laparoscopic-assisted gastrectomy and the effect of inflammatory cytokines on adhesion of gastric cancer cells to peritoneal mesothelial cells. Surg Endosc. 2010;24:2860–70.PubMedCrossRef
30.
Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol. 1993;50:15–9.PubMedCrossRef
31.
Asgeirsson KS, Olafsdottir K, Jonasson JG, Ogmundsdottir HM. The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine. 1998;10:720–8.PubMedCrossRef
32.
Giavazzi R, Nicoletti MI, Chirivi RG, Hemingway I, Bernasconi S, Allavena P, et al. Soluble intercellular adhesion molecule-1 (ICAM-1) is released into the serum and ascites of human ovarian carcinoma patients and in nude mice bearing tumour xenografts. Eur J Cancer. 1994;30A:1865–70.PubMedCrossRef
33.
Hayflick JS, Kilgannon P, Gallatin WM. The intercellular adhesion molecule (ICAM) family of proteins. New members and novel functions. Immunol Res. 1998;17:313–27.PubMedCrossRef
34.
Vigano P, Pardi R, Magri B, Busacca M, Di Blasio AM, Vignali M. Expression of intercellular adhesion molecule-1 (ICAM-1) on cultured human endometrial stromal cells and its role in the interaction with natural killers. Am J Reprod Immunol. 1994;32:139–45.PubMedCrossRef
35.
Gho YS, Kleinman HK, Sosne G. Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res. 1999;59:5128–32.PubMed
36.
Gho YS, Kim PN, Li HC, Elkin M, Kleinman HK. Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res. 2001;61:4253–7.PubMed
37.
Becker JC, Dummer R, Hartmann AA, Burg G, Schmidt RE. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol. 1991;147:4398–401.PubMed
Metadata
Title
Intraperitoneal Cytokine Level in Patients with Peritoneal Surface Malignancies. A Study of the RENAPE (French Network for Rare Peritoneal Malignancies)
Authors
Virginie Vlaeminck-Guillem, MD, PhD
Jacques Bienvenu, MD, PhD
Sylvie Isaac, MD
Blandine Grangier, AD
François Golfier, MD, PhD
Guillaume Passot, MD
Naoual Bakrin, MD
Claire Rodriguez-Lafrasse, MD, PhD
François-Noël Gilly, MD, PhD
Olivier Glehen, MD, PhD
Publication date
01-08-2013
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 8/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-2933-6

Other articles of this Issue 8/2013

Annals of Surgical Oncology 8/2013 Go to the issue

Hepatobiliary Tumors

Analysis of the Risk Factors of Untransplantable Recurrence After Primary Curative Resection for Patients with Hepatocellular Carcinoma

Gastrointestinal Oncology

Function-Preserving Gastrectomy for Early Gastric Cancer

Hepatobiliary Tumors

P16 Hypermethylation Predicts Surgical Outcome Following Curative Resection of Mid/Distal Bile Duct Cancer

Thoracic Oncology

Lack of Independent Significance of a Close (<1 mm) Circumferential Resection Margin Involvement in Esophageal and Junctional Cancer

Breast Oncology

The Prognostic Value of Lymph Node Ratio in Node-Positive Breast Cancer: A Dutch Nationwide Population-Based Study

Melanomas

Sentinel Node Biopsy in Thin and Thick Melanoma